You are here

  • Home
  • Archive
  • Volume 10, Issue 4
  • Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept

Article info

Article menu

This article has a correction. Please see:

Case report
Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept

Authors

  • Lee S Nguyen Research and Innovation of CMC Ambroise Paré (RICAP), Centre Medico-Chirurgical Ambroise Paré, Neuilly-sur-Seine, France PubMed articlesGoogle scholar articles
  • Marie Bretagne Department of Pharmacology, UNICO-GRECO Cardio-Oncology Program, Sorbonne Université, INSERM CIC-1901, AP.HP.Sorbonne, Pitié-Salpêtrière Hospital, Paris, France PubMed articlesGoogle scholar articles
  • Jennifer Arrondeau Assistance Publique-Hôpitaux de Paris (AP-HP), Cochin Hospital, Paris, France PubMed articlesGoogle scholar articles
  • Noel Zahr AP-HP, Inserm, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1901, Pharmacokinetics and Therapeutic Drug Monitoring Unit, UMR-S 1166, Sorbonne Université, Paris, France PubMed articlesGoogle scholar articles
  • Stephane Ederhy Cardiology Department and Sorbonne Université, GRC n°27, Groupe de Recherche en Cardio-Oncologie, AP-HP, Hôpital Saint-Antoine, Paris, France PubMed articlesGoogle scholar articles
  • Baptiste Abbar INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Medical Oncology, Institut Universitaire de Cancérologie, CLIP2 Galilée, Sorbonne Université, Paris, France PubMed articlesGoogle scholar articles
  • Bruno Pinna Department of Pharmacology, UNICO-GRECO Cardio-Oncology Program, Sorbonne Université, INSERM CIC-1901, AP.HP.Sorbonne, Pitié-Salpêtrière Hospital, Paris, France PubMed articlesGoogle scholar articles
  • Yves Allenbach Department of Internal Medicine and Clinical Immunology, Pitié Salpetriere Hospital, APHP, INSERM, Sorbonne University, Paris, France PubMed articlesGoogle scholar articles
  • Jean-Paul Mira Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Paris Centre, Médecine Intensive Réanimation, Université de Paris, Paris, France PubMed articlesGoogle scholar articles
  • Javid Moslehi Section of Cardio-Oncology & Immunology, Division of Cardiology and the Cardiovascular Research Institute, University of California San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Michelle Rosenzwajg INSERM UMRS_959; APHP. Sorbonne, Pitié-Salpêtrière Hospital, Clinical Investigation Center in Biotherapy (CIC-BTi) and Immunology-Inflammation-Infectiology and Dermatology Department (3iD), Sorbonne Université, Paris, France PubMed articlesGoogle scholar articles
  • Joe-Elie Salem Department of Pharmacology, UNICO-GRECO Cardio-Oncology Program, Sorbonne Université, INSERM CIC-1901, AP.HP.Sorbonne, Pitié-Salpêtrière Hospital, Paris, France PubMed articlesGoogle scholar articles

Citation

Nguyen LS, Bretagne M, Arrondeau J, et al
Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept
Journal for ImmunoTherapy of Cancer 2022;10:e004699. doi: 10.1136/jitc-2022-004699
Online issue publication 
November 02, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.